Novo Nordisk Raises Guidance on Strong Sales of Wegovy Pill

Danish pharmaceutical company Novo Nordisk has upwardly revised its financial guidance, driven by strong demand for the pill form of its weight-loss drug Wegovy, which was launched this year. The company's shares gained value on Wednesday following this development. The company stated that higher-than-expected adoption of the Wegovy pill has positively impacted its revenue outlook. This has increased investor confidence in Novo Nordisk and led to an upward movement in the share price. The guidance update indicates that the company's strategy to expand its product portfolio in weight management is beginning to bear fruit. The market acceptance of the oral treatment contributes to strengthening Novo Nordisk's position in this area. Investors will closely monitor whether the new guidance announced by the company is supported by operational performance. Not investment advice.

📊 NVO — Piyasa Yorumu

▲ up · 62%

Strong sales of the Wegovy pill and an upward revision to guidance are positive catalysts supporting the fundamental outlook for NVO. The price has risen 3.97% in the last 24 hours to 40.22, trading just below the SMA20 (40.27) and above the SMA50 (39.36). With an RSI of 57, it remains far from overbought territory, leaving room for momentum. However, the MACD (0.27) remains below its signal line (0.35), presenting a weak technical picture in the short term. An upward move within 1-3 days is possible due to the news impact, but breaking through SMA20 resistance is critical for confirmation.

RSI 14

57.3

MACD

0.27

24h Δ

3.97%

Canlı Grafikler